Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers May 25, 2017
Pharmacy Choice - News - U.S. Pharmaceutical Industry - May 25, 2017

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

5/25/17 - "Method and Pharmaceutical Composition for Inhibiting Pi3k/Akt/Mtor Signaling Pathway" in Patent Application Approval Process (USPTO 20170119747)
By a News Reporter-Staff News Editor at Women's Health Weekly A patent application by the inventors Duan, Lei; Levenson, Victor; Ying, GuoGuang, filed on November 22, 2016, was made available online on May 11, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application has not been assign
5/25/17 - Advanced Accelerator Applications Appoints Christine Mikail to Board of Directors
Ms. Mikail brings both a broad legal skillset and substantial business development experience in the pharmaceutical industry, stated Stefano Buono, Chief Executive Officer of AAA. Her expertise in these areas will augment the current board composition, as we continue to build a global enterprise and advance the development and commercializ
5/25/17 - AERI Is Awesome, GWPH Abuzz, FDA Panel Nod For PBYI
LONDON- Today's Daily Dose brings you news about Aerie Pharma's positive efficacy results from phase III study of its glaucoma drug candidate Roclatan; Alnylam's public offering and FDA panel's support for approval of Puma's breast cancer drug Neratinib. Shares of Aerie Pharmaceuticals Inc. climbed more than 27% in extended trading on Wednesday,...
5/25/17 - AG Paxton Announces $2 Million Settlement Payment to Baylor College of Medicine for Pediatric Neurological Research
Attorney General Ken Paxton today announced that the Baylor College of Medicine will receive $2 million from a settlement reached by Texas with Questcor Pharmaceuticals, Inc. Baylor College of Medicine will use the $2 million for funding related to innovative pediatric neurological research projects. In January, Texas, the Federal Trade Commission
5/25/17 - AG Paxton, 42 States Reach $33 Million Settlement with Johnson & Johnson Regarding Quality of Over-Counter Drugs
Attorney General Ken Paxton today announced that Texas will receive more than $2.2 million in a $33 million, 43- state settlement with pharmaceutical company Johnson& Johnson. From 2009 to 2011, alleged quality control lapses by McNeil-PPC, Inc., a wholly-owned subsidiary of Johnson& Johnson, resulted in recalls of many over-the-counter drugs for a
5/25/17 - Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals
FOR FURTHER INFORMATION CONTACT: Ila S. Mizrachi, FDA PRA Staff, Office of Operations, Food and Drug Administration, Three White Flint North, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-7726, SUPPLEMENTARY INFORMATION: The following is a list of FDA information collections recently approved by OMB under section 3507
5/25/17 - Agios Pharmaceuticals Inc Stake Boosted by Canada Pension Plan Investment Board [Emirates News Agency (WAM) (United Arab Emirates)]
Canada Pension Plan Investment Board raised its stake in Agios Pharmaceuticals Inc by 152.1% during the first quarter, according to its most recent 13 F filing with the SEC. Canada Pension Plan Investment Board owned about 0.07% of Agios Pharmaceuticals worth $1,781,000 as of its most recent SEC filing. Wells Fargo& Company MN boosted its position
5/25/17 - Akcea Announces Publication in The New England Journal of Medicine of Data with AKCEA-ANGPTL3-L Rx Showing Favorable Cardiometabolic Effects
Akcea Therapeutics, a wholly owned subsidiary of Ionis Pharmaceuticals, Inc., today announced the publication in The New England Journal of Medicine of key preclinical findings with angiopoietin-like 3- targeting drugs and Phase 1/ 2 clinical study results with AKCEA-ANGPTL3-L Rx. Furthermore, in preclinical studies, we have shown that targeting
5/25/17 - Arix Bioscience co-leads $45 million Series B investment round for Harpoon Therapeutics
LONDON, 25 May, 2017: Arix Bioscience plc, a global healthcare and life science company supporting medical innovation, today announced that Harpoon Therapeutics, a new Arix Group Business, has closed a Series B investment round raising $45 million. Arix Bioscience co-led the financing round with New Leaf Venture Partners, and additional new investo
5/25/17 - Bharat Book Bureau: Global Depth Filtration Market by Media
The global depth filtration market is projected to reach USD 2.96 billion by 2022 from USD 1.70 billion in 2017, at a CAGR of 11.7% from 2017 to 2022. Increasing demand for biopharmaceuticals and increasing R&D expenditure in the biopharmaceutical industry are the major factors driving the growth of the global depth filtration market.
5/25/17 - BioLineRx Reports First Quarter 2017 Financial Results
BioLineRx Ltd., a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the first quarter ended March 31, 2017. Interim results support BL-8040 as a one-day dosing regimen for rapid mobilization of substantial amounts of stem cells, a significant improvement over the current...
5/25/17 - Blake Insomnia Therapeutics Inc. Announces Appointment of Kyle Sarwal and Ajit Johal to its Board of Directors
Blake Insomnia Therapeutics Inc. a New York based pharmaceutical company is pleased to announce the appointment of Kyle Sarwal and Ajit Johal to its Board of Directors.. Mr. Sarwal is a director and business development expert for SAJO Consulting, a company with management, research, scientific, and regulatory expertise. Ajit brings to Blake I
5/25/17 - Cancer resistance firm TP Therapeutics reaps $45M in third round [Arab Finance (Egypt)]
The company was co-founded in 2013 by ex- Pfizer scientist Jean Cui, Ph.D., who was behind the development of the drugmaker`s $560 million drug Xalkori and is hoping to repeat that success with TP`s lead candidate, TPX-0005. Proceeds from the third-round financing, co-led by Lilly Asia Ventures, OrbiMed Advisors, and S.R. If TP`s prediction pans ou
5/25/17 - ContraFect Announces Initiation of Phase 2 Study Evaluating CF-301 in Patients with Staphylococcus aureus Bacteremia
ContraFect Corporation, a biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced the initiation of an international Phase 2 study evaluating its first-in-class lysin, CF-301, as a potential treatment of Staphylococcus aureus...
5/25/17 - Curis Announces Presentations Related to CA-170 and CUDC-907 at 2017 ASCO Annual Meeting
Curis, Inc., a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced the presentation of a poster describing the Phase 1 trial of CA-170, an oral small molecule dual inhibitor of immune checkpoints PD-1 and VISTA, in the treatment of patients wi
5/25/17 - Don't let fake health news impact your family
It appears parents in Vermont are listening. In the current school year, 94 percent of Vermont's children in grades K-12 have received all required vaccines. Prior to approval by the Food and Drug Administration, manufacturers must demonstrate vaccine safety.
5/25/17 - Eatontown drug execs will tell all in price-fixing case [Asbury Park Press, N.J.]
May 24 Two former drug company executives from Monmouth County reached a settlement and will cooperate with investigators in a price-fixing case against some of the nation's biggest generic drug makers, authorities said Wednesday. Jeffery Glazer and Jason Malek, who led Heritage Pharmaceuticals in Eatontown, agreed to provide documents, testimony
5/25/17 - Elite Pharmaceuticals SequestOx? Study Results Expected in July
Elite Pharmaceuticals, Inc., today announced that top-line results for its reformulated SequestOx? study are expected in July 2017. Patient disqualification and subsequesnt subject recruitment issues extended the completion date for the study. The study, which began in March 2017, is a pivotal, open-label, randomized, single-dose, three-way, cr
5/25/17 - FDA approves first treatment for giant cell arteritis [T-break Tech (Middle East)]
It is the first drug of its kind to be made available by the Food and Drug Administration to treat adults with this condition, although it is already available in the United States in the same form for patients with severely active rheumatoid arthritis. Announcing the decision, Badrul Chowdhury, director of the division of pulmonary, allergy, and r
5/25/17 - Fresh off two new FDA nods, Merck`s high-flying Keytruda nets priority status in stomach cancer [Syrian Arab News Agency]
In a month that`s featured three FDA approvals for Keytruda, the immuno-oncology med has netted a speedy review for the therapy in stomach cancer. The FDA will hand down an approval decision by September 22, it said. Five checkpoint inhibitorsKeytruda; Opdivo; Roches Tecentriq; Pfizer and Merck KGaAs Bavencio; and AstraZenecas Imfinzinow boast at l
5/25/17 - Gainers & Losers Of May 24: PBYI, INO, NVCR, AKAO, NBIX...
News: The FDA panel has supported approval of the Company's breast cancer drug Neratinib. The FDA panel voted 12- 4 to recommend approval of Neratinib for the extended adjuvant treatment of HER2-positive early stage breast cancer. The FDA usually follows the recommendations of its advisory panels, although it is not required to do so.
5/25/17 - Growing Importance of SNP Genotyping in the Drug Development Process Boost Genotyping Market
Genotyping Market report categorizes the global market by Products, Application, Technology& GeographySeattle, WA 05/24/2017 The " Genotyping Market by Technology, Application, Products- Global Forecast to 2020" analyzes and studies the major market drivers, restraints, and opportunities in North America, Europe, Asia, and Rest of the World.
5/25/17 - GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Announce Publication of Groundbreaking Study of Epidiolex (cannabidiol) in The New England Journal of Medicine
-First well-controlled clinical study of cannabidiol in Dravet syndrome, a rare, severe type of epilepsy with no FDA- approved treatments-. GW Pharmaceuticals plc, a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary...
5/25/17 - Hepatitis has been on the rise
Hepatitis has been on the rise in Swain County and other parts of the country. The rise of injection drug use in Swain County and the rest of the United States is linked to the spread of Hepatitis C. In Swain County, there is a high incidence of drug use both prescription and non-prescription drugs, and injection is becoming more common among those
5/25/17 - Innovus Pharma Launches AllerVarx, a Clinically Proven Supplement for the Relief of Allergy Symptoms, in the United States [Sport360]
Innovus Pharmaceuticals, Inc., an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve mens and women`s health and respiratory diseases, today announced the launch of AllerVarx in the U.S. AllerVarx is a clinically proven supplement,...
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
Telepharmacy- Remote Delivery of Pharmacy Services
This lesson is supported by:
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement